Latest Articles

Publication Date
All News Scientific
IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer - Yahoo Finance

IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer Yahoo Finance

Published: Dec. 10, 2024, 11 a.m.
Read Full Article
IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer - PR Newswire

IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer PR Newswire

Published: Dec. 10, 2024, 11 a.m.
Read Full Article
HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer - GlobeNewswire

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer GlobeNewswire

Published: Dec. 3, 2024, 10:01 a.m.
Read Full Article
HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer - Yahoo Canada Finance

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer Yahoo Canada Finance

Published: Dec. 3, 2024, 10 a.m.
Read Full Article
HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer - Yahoo Finance

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer Yahoo Finance

Published: Dec. 3, 2024, 10 a.m.
Read Full Article
HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer - Yahoo Finance UK

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer Yahoo Finance UK

Published: Dec. 3, 2024, 10 a.m.
Read Full Article
Relugolix Combination Therapy Improves Pain, Functioning, and Quality of Life in Women with... - Medical Dialogues

Relugolix Combination Therapy Improves Pain, Functioning, and Quality of Life in Women with... Medical Dialogues

Published: Nov. 11, 2024, 3:45 p.m.
Read Full Article
Relugolix Combination Therapy Improves Pain, Functioning, and Quality of Life in Women with Endometriosis: Study - Medical Dialogues

Relugolix Combination Therapy Improves Pain, Functioning, and Quality of Life in Women with Endometriosis: Study Medical Dialogues

Published: Nov. 11, 2024, 3:45 p.m.
Read Full Article
Lisata Therapeutics, University of Cincinnati explore combination treatment for Endometriosis - ca.proactiveinvestors.com

Lisata Therapeutics, University of Cincinnati explore combination treatment for Endometriosis ca.proactiveinvestors.com

Published: Oct. 31, 2024, 5:16 p.m.
Read Full Article
Lisata Therapeutics, University of Cincinnati explore combination treatment for Endometriosis - Proactive financial news

Lisata Therapeutics, University of Cincinnati explore combination treatment for Endometriosis Proactive financial news

Published: Oct. 31, 2024, 5:16 p.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!